FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2101004558> ?p ?o ?g. }

• W2101004558 endingPage "770" @default.
• W2101004558 startingPage "755" @default.
• W2101004558 abstract "Gram-negative resistance has reached a crucial point, with emergence of pathogens resistant to most or all available antibiotics. Ceftazidime-avibactam is a newly approved agent combining ceftazidime and a novel β-lactamase inhibitor with activity against multidrug-resistant gram-negative bacteria. Avibactam has increased potency and expanded spectrum of inhibition of class A and C β-lactamases relative to available β-lactamase inhibitors, including extended-spectrum β-lactamases, AmpC, and Klebsiella pneumoniae carbapenemase (KPC) enzymes. Avibactam expands ceftazidime's spectrum of activity to include many ceftazidime- and carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa. Early clinical data indicate that ceftazidime-avibactam is effective and well tolerated in patients with complicated urinary tract infections (cUTIs) and complicated intraabdominal infections (cIAI). In a phase II trial of patients with cUTIs, ceftazidime-avibactam produced similar rates of clinical and microbiologic success compared with imipenem-cilastatin (70.5% and 71.4% microbiologic success rates, respectively). Likewise, patients receiving ceftazidime-avibactam plus metronidazole in a phase II study of patients with cIAI had similar response rates to those receiving meropenem (91.2% and 93.4% clinical success rates, respectively). Based on available in vitro, in vivo, and phase II trial data, as well as preliminary phase III trial results in ceftazidime-resistant, gram-negative cUTI and cIAI, ceftazidime-avibactam received U.S. Food and Drug Administration approval for treatment of cUTI, including pyelonephritis, and cIAI, in combination with metronidazole, in adult patients with limited or no alternative treatment options. The approved dosage, ceftazidime 2 g-avibactam 0.5 g administered as a 2-hour infusion every 8 hours, was selected based on pharmacodynamic analysis and available clinical data. This dosage is under further investigation in patients with cUTI, cIAI, and nosocomial or ventilator-associated pneumonia. The current body of evidence suggests that ceftazidime-avibactam is a promising addition to our therapeutic armamentarium with potential to answer an urgent unmet medical need. Further data in highly resistant gram-negative infections, particularly those caused by KPC-producing Enterobacteriaceae, are needed. As it is introduced into clinical use, careful stewardship and rational use are essential to preserve ceftazidime-avibactam's potential utility." @default.
• W2101004558 created "2016-06-24" @default.
• W2101004558 creator A5010659587 @default.
• W2101004558 creator A5043553812 @default.
• W2101004558 creator A5084829703 @default.
• W2101004558 date "2015-08-01" @default.
• W2101004558 modified "2023-10-14" @default.
• W2101004558 title "The β-Lactams Strike Back: Ceftazidime-Avibactam" @default.
• W2101004558 cites W1480294397 @default.
• W2101004558 cites W1518311090 @default.
• W2101004558 cites W1895007034 @default.
• W2101004558 cites W1918593164 @default.
• W2101004558 cites W1974451627 @default.
• W2101004558 cites W1976865470 @default.
• W2101004558 cites W1979976798 @default.
• W2101004558 cites W1987192444 @default.
• W2101004558 cites W1989592886 @default.
• W2101004558 cites W1992255321 @default.
• W2101004558 cites W2004431245 @default.
• W2101004558 cites W2005000232 @default.
• W2101004558 cites W2006629833 @default.
• W2101004558 cites W2013132592 @default.
• W2101004558 cites W2018229558 @default.
• W2101004558 cites W2024033157 @default.
• W2101004558 cites W2026414172 @default.
• W2101004558 cites W2050886517 @default.
• W2101004558 cites W2059490858 @default.
• W2101004558 cites W2060495363 @default.
• W2101004558 cites W2062362165 @default.
• W2101004558 cites W2068735589 @default.
• W2101004558 cites W2072361904 @default.
• W2101004558 cites W2097533517 @default.
• W2101004558 cites W2098742478 @default.
• W2101004558 cites W2100232903 @default.
• W2101004558 cites W2103929713 @default.
• W2101004558 cites W2107668809 @default.
• W2101004558 cites W2116800779 @default.
• W2101004558 cites W2119561074 @default.
• W2101004558 cites W2126873899 @default.
• W2101004558 cites W2128484737 @default.
• W2101004558 cites W2129842338 @default.
• W2101004558 cites W2133786572 @default.
• W2101004558 cites W2140099773 @default.
• W2101004558 cites W2140518380 @default.
• W2101004558 cites W2141204124 @default.
• W2101004558 cites W2144878979 @default.
• W2101004558 cites W2153512397 @default.
• W2101004558 cites W2155745552 @default.
• W2101004558 cites W2157019531 @default.
• W2101004558 cites W2157660723 @default.
• W2101004558 cites W2160484574 @default.
• W2101004558 cites W2163292670 @default.
• W2101004558 cites W2171396020 @default.
• W2101004558 cites W2171447404 @default.
• W2101004558 cites W312223655 @default.
• W2101004558 doi "https://doi.org/10.1002/phar.1622" @default.
• W2101004558 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4545577" @default.
• W2101004558 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26289307" @default.
• W2101004558 hasPublicationYear "2015" @default.
• W2101004558 type Work @default.
• W2101004558 sameAs 2101004558 @default.
• W2101004558 citedByCount "147" @default.
• W2101004558 countsByYear W21010045582015 @default.
• W2101004558 countsByYear W21010045582016 @default.
• W2101004558 countsByYear W21010045582017 @default.
• W2101004558 countsByYear W21010045582018 @default.
• W2101004558 countsByYear W21010045582019 @default.
• W2101004558 countsByYear W21010045582020 @default.
• W2101004558 countsByYear W21010045582021 @default.
• W2101004558 countsByYear W21010045582022 @default.
• W2101004558 countsByYear W21010045582023 @default.
• W2101004558 crossrefType "journal-article" @default.
• W2101004558 hasAuthorship W2101004558A5010659587 @default.
• W2101004558 hasAuthorship W2101004558A5043553812 @default.
• W2101004558 hasAuthorship W2101004558A5084829703 @default.
• W2101004558 hasBestOaLocation W21010045582 @default.
• W2101004558 hasConcept C104317684 @default.
• W2101004558 hasConcept C126322002 @default.
• W2101004558 hasConcept C2775933652 @default.
• W2101004558 hasConcept C2776685102 @default.
• W2101004558 hasConcept C2776968632 @default.
• W2101004558 hasConcept C2777058267 @default.
• W2101004558 hasConcept C2777396551 @default.
• W2101004558 hasConcept C2777406300 @default.
• W2101004558 hasConcept C2777637488 @default.
• W2101004558 hasConcept C2779375183 @default.
• W2101004558 hasConcept C2910641391 @default.
• W2101004558 hasConcept C501593827 @default.
• W2101004558 hasConcept C523546767 @default.
• W2101004558 hasConcept C54355233 @default.
• W2101004558 hasConcept C547475151 @default.
• W2101004558 hasConcept C55493867 @default.
• W2101004558 hasConcept C71924100 @default.
• W2101004558 hasConcept C86803240 @default.
• W2101004558 hasConcept C89423630 @default.
• W2101004558 hasConcept C94665300 @default.
• W2101004558 hasConcept C98274493 @default.
• W2101004558 hasConceptScore W2101004558C104317684 @default.

• next